Background: Drug-resistant epilepsy (DRE) is usually related to focal epilepsy (FE) and is present in up to 30% of patients. Several studies have found high rates of depressive symptoms and poor health related quality of life (HRQOL) in DRE patients but little information is available on these aspects for Spain. Objective: To determine the prevalence of depressive symptoms in a cohort of Spanish patients with DRE and evaluate their HRQOL in comparison with patients with controlled FE (CFE). Methods: This observational cross-sectional study analyzed FE patients, with and without DRE, recruited from different Spanish neurology outpatient clinics. Presence of depressive symptoms was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Beck Depression Inventory-II (BDI-II). HRQOL was evaluated using the Quality of Life in Epilepsy Inventory (QOLIE-31). Results: 515 patients (DRE = 248) were included. Mean (SD) age was 44.3 (15.4) years and 50.5% were male. Overall, 15.9% had a previous diagnosis of depressive symptoms (DRE = 22.6%; CFE = 9.7%, p < 0.001). 
Introduction
Focal epilepsy has been estimated to account for 20-66% of incident cases (Banerjee et al., 2009) . Prevalence rates for epilepsy in Spain are between 5 and 10/1000, giving a total of approximately 400,000 individuals with the condition, of which 57% have focal epilepsy (Sempere et al., 2002) . Despite the availability of effective treatments for epilepsy (Glauser et al., 2006; Johannessen and Ben-Menachem, 2006) , it has been estimated that anywhere between 15% and 40% of patients fail to achieve adequate seizure control (Brodie and Kwan, 2002; Kwan and Brodie, 2004; Picot et al., 2008; Rufo-Campos et al., 2008) . Patients with focal epilepsy in particular are more likely to have drug-resistant epilepsy (DRE) (Picot et al., 2008) . The lack of satisfactory seizure control in these patients can have a substantial negative impact on patient health related quality of life (HRQOL), with studies showing poorer HRQOL in those with frequent seizures (at least one a month) than in those with infrequent or no seizures (Baker et al., 1997; Villanueva et al., 2013) . Seizure severity has also been shown to be a good predictor of poorer HRQOL (Taylor et al., 2011) .
From a patient perspective, the combination of poor seizure control and higher rates of depressive symptoms can have a highly deleterious effect on HRQOL (Jacoby et al., 2009; Park et al., 2010; Taylor et al., 2011) , and scores on depression scales have been shown to be the strongest and most consistent predictors of HRQOL in epilepsy patients (Tracy et al., 2007; Luoni et al., 2011) . To date, however, there have been relatively few studies into the prevalence of depression in DRE or its impact on HRQOL, although a recently published study found a rate of major depression in DRE patients of 23% compared to 8.3% in non-DRE patients (Villanueva et al., 2013) . The primary objective of the present study was to determine the prevalence of depressive symptoms in patients with DRE compared to those with controlled focal epilepsy (CFE) and evaluate the impact of depressive symptoms on HRQOL in the two groups.
Secondary study objectives were to analyze the correlation between the Montgomery Asberg (MADRS) and Beck Depression Inventory (BDI), to investigate socio-demographic and clinical factors related to the severity of depressive symptoms in these patients, to describe HRQOL in the two groups, and to explore the socio-demographic and clinical factors associated with poor HRQOL.
Methods

Study design
This was an observational, cross-sectional, multicenter cohort study carried out in Spanish neurology outpatient clinics. Patients were recruited consecutively by a total of 130 neurologists in 99 centers throughout Spain and assigned to one of two study groups (DRE or CFE). In accordance with International League Against Epilepsy (ILAE) guidelines, patients with DRE were defined as those in which sustained seizure freedom was not achieved after adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether monotherapies or in combination) (Kwan et al., 2010) . Patients with CFE were those whose seizures had been controlled at least during the previous 12 months. Patients were included in the study between November 2011 and August 2012 and data was collected either from medical records or by questionnaires completed by the patient at the time of the study visit.
The study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans, and ethical approval was obtained from the Ethics Committee of one of the participating hospitals.
Study population
To be included in the study patients had to be aged 18 years or over, have a confirmed clinical diagnosis of focal epilepsy, and have provided signed informed consent to participate. Patients were excluded if they had a chronic disease that could interfere with the study results, such as heart disease, diabetes, respiratory failure, chronic pain, rheumatologic diseases or digestive diseases, or if, in the opinion of the clinical investigator, they had difficulties in understanding, reading, and writing or a degree of cognitive impairment which would prevent them from completing the study questionnaires.
Sample size
The study sample size was designed to determine the prevalence of depressive symptoms in patients with drug-resistant focal epilepsy, and to evaluate the impact of depressive symptoms on HRQOL. The prevalence of depressive symptoms in patients with focal epilepsy was estimated at 43% (Kanner et al., 2004) , which meant that for a precision of 4.5 points and a significance level of 0.05, a minimum sample size of 465 patients would be required. Assuming 10% of invalid questionnaires, the necessary sample size was 500 patients, or 250 each in the CFE and DRE groups.
Study endpoints and variables
The study's primary endpoint was the prevalence of depressive symptoms. At the time this study was initiated the Montgomery-Asberg Depression Rating Scale (MADRS) (Lobo et al., 2002) and the Beck Depression Inventory (BDI-II) (Beck et al., 1996; Sanz et al., 2003) had been frequently used in the epilepsy population. In addition, most epilepsy specialists in Spain are familiar with these scales, using them regularly in clinical practice and drug trials. Because of this we chose MADRS and BDI-II instead of other depression scales for this study. The MADRS is an interview-administered questionnaire consisting of 10 items which measure 10 different depressive symptoms over the past week. Each symptom is evaluated on a 7 point Likert scale and the total score ranges from 0 points (no depression) to 60 (maximum level of depression). A score below 10 points is considered to indicate absence of depressive disorder, so for the purposes of this study depressive symptoms was considered to be present in any patient with a score of 10 or above.
The BDI-II is a widely used self-administered scale consisting of 21 items to evaluate the severity of depressive symptoms. Each BDI-II item consists of four statements, scored 0-3, with higher scores indicating increasing symptom severity. Respondents are instructed to describe the way they have been feeling during the past two weeks. The final score can range between 0 and 63 and a score of 10 points or over was considered to indicate presence of depressive symptoms.
In order to assess the effect of depressive symptoms on HRQOL, patients also completed the Quality of Life in Epilepsy Inventory (QOLIE-31) (Cramer et al., 1998; Torres et al., 1999) . This self-administered instrument measures disease-specific HRQOL in patients with epilepsy and consists of 31 items covering seven HRQOL dimensions (seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive disorders, medication effects, and social functioning). The overall score ranges from 0 (worst possible HRQOL) to 100 (best possible HRQOL). Although pre-defined cut-points are not available with the questionnaire, studies in epilepsy patients have suggested the following possible categorization: excellent (91-100), very good (81-90), good (71-80), fair (61-70), and poor (≤60) (Pérez Galdós, 2010) .
Socio-demographic variables collected in the study included age (in years), gender, ethnicity (Caucasian, Hispanic, African, Asian, other), educational level, employment status, residence, and impact of disease on place of residence. Clinical variables included general clinical characteristics such as current weight, height, body mass index (BMI), and presence of concomitant chronic diseases (cardiovascular, gastrointestinal/hepatic, endocrine/metabolic, genito-urinary, infectious, musculoskeletal, neurological/psychiatric, respiratory, neoplastic, other). Epilepsy and depressive symptoms related variables included time since diagnosis of epilepsy, epilepsy type, drug treatment for epilepsy, clinical diagnosis of depressive symptoms (yes/no), date of diagnosis of depressive symptoms or date of onset of depressive symptoms, drug treatment for depressive symptoms, and family history of depressive symptoms. Information on alcohol and drug consumption was also collected.
Statistical analysis
To describe the sample and to compare groups on study endpoints, continuous variables were described using means and standard deviations, or medians and interquartile ranges as appropriate. Categorical variables were described using absolute values and percentages. Student's t test and analysis of variance (ANOVA) or their non-parametric equivalent, were used for between group comparisons of continuous variables, and a chi-square test for linear trend (Mantel-Haenszel) or Fisher's exact test were used to analyze categorical variables. In post-hoc comparisons, a Bonferroni adjustment was used to correct for multiple comparisons. In all statistical tests with outcome variables statistical significance was set at p < 0.01.
The prevalence of depressive symptoms was analyzed based on responses to the MADRS and BDI-II. Cases were defined as those scoring 10 or more on MADRS or the BDI-II. Prevalence was calculated as the number of cases divided by the total population included for analysis. As treatment for depressive symptoms could lead to lower scores on the MADRS and BDI-II, we also calculated prevalence rates for depressive symptoms in which we included as cases any patient who was also taking medication for depressive symptoms, whatever their score on the screening questionnaires.
To analyze the relationship between socio-demographic and clinical characteristics and scores on the depression and HRQOL scales, we initially performed bivariate tests of association using ANOVA for categorical variables and Pearson or Spearman correlations for continuous variables. Sociodemographic and clinical variables showing a statistically significant relationship (p ≤ 0.1) with depressive symptoms or HRQOL in bivariate analysis were then included in a linear regression model to determine whether they independently contributed to depressive symptoms and HRQOL scores. Variables that improved model fit and which were significant at p < 0.05 in the multivariate model were selected using the backward method. Model fit was assessed using r-squared. All analyses were performed using the statistical package SAS v. 9.2 for Windows.
Results
A total of 515 patients with focal epilepsy were included. Of those, 267 (51.8%) had CFE and 248 (48.2%) had DRE. Table 1 shows the socio-demographic characteristics of the sample as a whole and by sub-group. In the overall sample, mean (SD) patient age was 44.3 (15.4) years and 50.5% were male, primarily Caucasian, with primary level education (32.7%), and currently employed (39.2%). 91.7% of the sample were living with family members and 20.1% reported that the disease affected their living arrangements. There were statistically significant differences between the two study groups in terms of employment situation (39.2% employed in the CFE group compared to 29.0% in the DRE group; p < 0.001) and whether illness affected the place of residence (20.1% in CFE vs 29.7% in DRE; p < 0.001). Table 2 shows the sample's clinical characteristics. In approximately three-quarters of the patients, focal epilepsy was the initial diagnosis and almost all were receiving antiepileptic treatment at the time of the study visit, with a mean of 2 antiepileptic drugs (AED). The number of AEDs was significantly higher in the DRE group. The proportion of patients with co-morbidities was very similar between the two study groups (37.5% in CFE and 33.3% in DRE) and 15.9% of patients had a previous diagnosis of clinical depressive symptoms; the proportion of patients with a prior diagnosis of clinical depressive symptoms was substantially higher in the DRE group than in the CFE group (22.6% vs 9.7%, respectively; p < 0.001). Fig. 1 and Table 3 show the prevalence of depressive symptoms in the two study groups according to the MADRS and BDI-II, using raw scores and scores adjusted to take into account patients taking medication for depressive symptoms. Both questionnaires showed much higher rates of depressive symptoms in the DRE group. Using the MADRS scale, prevalence of depressive symptoms in the DRE group was almost double that of the CFE group (59.3% vs 30.3%, respectively, using unadjusted data and 62.1% vs 32.6% using adjusted data; p < 0.001). Similar results were seen with the BDI, with an overall depressive symptoms rate of 48.1% using the ≥10 point threshold, and considerably higher rates of depressive symptoms in the DRE group compared to CFE patients (61.9% vs 35.3%, respectively, using unadjusted data, and 64.8% vs 37.2% using adjusted data; p < 0.001).
With regard to the degree of association and correlation between the two scales (see Fig. 2 ), we found an overall prevalence rate for depressive symptoms of 37.2% when we only included patients who were confirmed as cases on both scales. The Pearson correlation coefficient between the two scales was high, at r = 0.80. Multivariate modeling showed that variables associated with higher MADRS and BDI-II scores (more severe depressive symptoms) included being in the DRE group, having a lower level of education, being unemployed or on temporary sick leave, receiving treatment for depressive symptoms, and having certain types of co-morbid illnesses. In both cases, the strongest contributor to higher MADRS and BDI-II scores was having a diagnosis of depressive symptoms but being untreated for the condition. Both models showed acceptable goodness of fit.
Regarding the HRQOL of patients with DRE and CFE, those with adequately controlled seizures experienced considerably better HRQOL than those with poorer control (see Fig. 3 ). This was true on all dimensions of the QOLIE-31 and on the overall score (mean [SD] of 69.9 [16.5] for the CFE group and 54.2 [18.9] in the DRE group). All differences between the two groups on QOLIE-31 dimensions and on overall score were statistically significant (p < 0.001).
As shown in Fig. 4 , the presence of depressive symptoms led to poorer QOLIE-31 scores in both study groups. than those with CFE as did those with higher levels of depressive symptoms. Even minimal signs of depressive symptoms on either of the depression scales led to a substantial reduction in QOLIE-31 scores. The multivariate model used showed a high goodness of fit, and explained 68.7% of the variance in the dependent variable (QOLIE-31 score). Further analysis showed that the QOLIE-31 score decreased by almost one point for each one point increase on the BDI-II, compared to a decrease of one point on QOLIE-31 for each two point increase on the MADRS, suggesting that differences in score on the BDI-II had a greater impact on QOLIE-31 scores (data not shown).
Discussion
In this study, we provide further evidence of the prevalence of depression and depressive symptoms in patients with DRE compared to patients with CFE in a Spanish cohort. After including patients who were receiving some form of anti-depressant medication, we found a significant rate of depressive symptoms which was much higher in the DRE group than in patients with CFE. We also found that QOLIE 31 dimensions and overall scores were considerably worse in DRE patients than in CFE patients. Furthermore, we observed that patients with depressive symptoms have worse HRQOL even when seizures are controlled. This indicates a strong correlation between depressive symptoms, HRQOL and seizure control. The lowest HRQOL was found in patients with DRE and depressive symptoms. Risk factors for the presence of depressive symptoms included having a lower level of education, being on sick leave or unemployed, and having certain co-morbidities (diseases of the blood and blood forming organs, and cerebrovascular disease). While the study design did not allow us to determine whether these were causal factors for depressive symptoms, the results do provide an indication of characteristics to take into account when deciding on the likelihood of depressive symptoms in individual patients. Further research is needed, on the other hand, to confirm the extent to which co-morbidities such as hematological or cerebrovascular diseases are in fact independent risk factors for depressive symptoms, as the numbers in the present sample in both cases were small, and extreme results in such small numbers could have unduly biased the results. This is one of very few epidemiological studies of this type performed in a Spanish population. We consider our findings to be clinically relevant because they highlight aspects related to the clinical practice and management of patients with FE which may require further attention. The results of the current study underline the widespread nature of depressive symptoms in FE patients, particularly those with DRE, and provide further evidence of the association between depressive symptoms, HRQOL and seizure control and thus in the evolution of the disease. Furthermore, they suggest that depressive symptoms may be considerably undertreated in this population, a very important finding considering how it can modify the prognosis of epilepsy. Although we found prevalence rates of almost 50% for depressive symptoms, only 15.9% of the overall sample had a previous clinical diagnosis of depressive symptoms, indicating that a high percentage of patients were underdiagnosed and undertreated. This has been observed in other studies; for example Friedman et al. (2009) , using systematic screening, found at least 65% of patients with previously undiagnosed depression, while Boylan et al. (2004) reported an underdiagnosis rate of 37%, with only 17% of patients receiving anti-depressants.
The study results confirm previous findings of a tendency toward higher rates of depressive symptoms in epilepsy patients, particularly in DRE patients, though some earlier studies found lower overall rates than those reported here. Picot et al. (2008) found rates of psychiatric disorders, mainly anxiety or depression, of 37% in patients with DRE and 18.9% in patients with controlled epilepsy, while Villanueva et al. (2013) reported rates of 23% versus 8.3%, respectively, for the same groups (Villanueva et al., 2013) . Kanner et al. (2004) , on the other hand, reported depression rates of 43% in DRE patients and lifetime prevalence rates of 30% to 35% in general samples of people with epilepsy (Kanner et al., 2012) , rates which are closer to those found in our study. Other authors have noted the variability in prevalence rates for depression reported in different studies, with a range from 8% to 48% (Hermann et al., 2000) . To some extent, rates will depend on methodology. For example, Picot et al. (2008) based their findings on physician reports of psychiatric disorders, while Villanueva et al. (2013) used the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) (Gilliam et al., 2006) to identify cases of depression. The cut-points for depression used with an instrument can also impact depression rates. In our study, using the standard recommended cut-point of 10 points on the BDI-II (Sanz et al., 2003) led to a prevalence rate of 50.5% after including patients receiving medication for depressive symptoms; this compared to a rate of 40% using the cutpoint of 12 points recommended by Jones and colleagues (Jones et al., 2005) . It should also be remembered that, while respondents scoring under the cut-point on the BDI-II are very unlikely to have major depression (excellent negative predictive value), approximately 50% of those scoring above the cut-point are likely to have major depression (Jones et al., 2005) . As the importance of detecting depressive symptoms in patients with epilepsy has been clearly demonstrated in several studies, we believe it is essential to work toward a more standardized methodology for its detection. Part of that would involve determining the best scale to evaluate depressive symptoms in this group of patients. That would help minimize the variability in results and improve comparability between studies.
Furthermore, given the relevant prevalence of depressive symptoms in this population, we should reinforce the importance of its identification and the need to promptly initiate management strategies, such as identifying AEDs that could be causing or worsening depressive symptoms, prescribing antidepressants or referring patients to psychiatrists or psychotherapy, that in some cases show better long term benefits over medication.
A strong point of the present study was the use of two different scales to assess the presence of depressive symptoms. The results were similar in terms of the rates of depressive symptoms identified, suggesting that the findings were robust. Both measures also showed similar results when included in multivariate modeling to test the impact of depressive symptoms on HRQOL. As in previous studies, we found that the presence of depressive symptoms was the strongest predictor of poor HRQOL in these patients (Tracy et al., 2007; Luoni et al., 2011) . It is also interesting to note that the presence of minimal depressive symptoms on the MADRS or the BDI-II had a significant negative effect on QOLIE-31 scores. This suggests that even moderate improvements in depressive symptoms might lead to considerable gains in HRQOL. Another strong point of the study was the relatively large sample size and the fact that patients were included from a large number of centers throughout Spain. Both of these aspects support the generalizability of the results.
Limitations of the study include the fact that, due to the study design, it was not possible to determine the direction of any effect of the variables in the multivariate models on the dependent variables. Thus, it is not possible to determine, for example, whether DRE is a contributing factor to depressive symptoms, or vice versa. Some current thinking suggests a bi-directional relationship (Kanner, 2011) , whereby the presence of depressive symptoms might be one of a series of risk factors for poor response to therapy with AEDs (Petrovski et al., 2010) . Another limitation of the study is that we did not collect information on seizure frequency prior to inclusion. It was therefore not possible to determine the possible effect of seizure frequency on QOLIE-31 scores or to examine its association with MADRS and BDI-II scores. Including seizure frequency in modeling of the QOLIE-31 score may have reduced the impact of depressive symptoms to some extent, but other studies have shown that depressive symptoms have a stronger effect on HRQOL than seizure frequency (Tracy et al., 2007; Luoni et al., 2011) .
Finally, generalizability of results may be somehow limited because the sample of participating sites and the number of patients per center were no chosen following a population and geography-based sampling methodology; however, the large number of investigators and healthcare locations with geographical spread across Spain, and consecutive recruitment of patients make it unlikely that any serious bias may reduce significantly results and conclusions robustness.
In conclusion, this study provides further evidence of the pervasive nature of depressive symptoms among people with epilepsy and, particularly, in those with DRE. Prompt identification and treatment of affected individuals is advised. Quality of life is most strongly affected in those with DRE and self-reported depressive symptoms. Despite the growing evidence of the correlation between depressive symptoms and epilepsy, it appears to be still underdiagnosed and undertreated. The co-morbid nature of depressive symptoms and epilepsy suggests the need for a coordinated approach to treatment and future randomized studies should determine the extent to which appropriate management of depressive symptoms in patients with DRE affects HRQOL and seizure control.
